ANXA1 and dry eye syndrome: In conclusion, our findings demonstrate that the glucocorticoid effector protein AnxA1 has potential in prevention or as a new treatment for dry eye, allergic conjunctivitis and other forms of ocular surface inflammation through its effect on conjunctival goblet cells.